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associated with endometrial cancer. Small-cell carcinoma of the endometrium is relatively rare but aggressive,
and often presents a component of endometrioid carcinoma, and is not generally associatedwith serous carcino-
ma. Herein, we report a case of 74-year-old African-American female, who presented with intermittent post-
menopausal bleeding for N1-month. She underwent robotic-assisted laparoscopic hysterectomy, bilateral
salpingo-oophorectomy, sentinel lymph node mapping, and pelvic-and-aortic lymphadenectomy. Final patholo-
gy was consistent with serous carcinoma of the endometrium in combination with neuroendocrine small-cell
carcinoma. This extremely rare combination of tumors presents a challenge for treatment. Themainstay of treat-
ment seems to be surgery followed by chemotherapy ± radiation therapy. To our knowledge, it represents an
under-reported area of gynecological medicine.
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Endometrial serous carcinomas, which compromise approximately
10% of endometrial carcinomas, are very clinically aggressive (Clement
and Young, 2004). This tumor type constitutes 40% of all deaths and re-
currences associated with endometrial cancer (Fader et al., 2010).
Small-cell carcinoma (SCC) of the endometrium is relatively rare but
aggressive, and often presents a component of endometrioid carcinoma,
and is not generally associated with serous carcinoma. The endometri-
um is the least common site of this disease in the female genital tract
(Matsumoto et al., 2011). Histologically, small-cell neuroendocrine tu-
mors present very similarly in the endometrium as it does, more com-
monly, in the lung (Kumar, 1984). An optimal treatment for patients
with SCC has not yet been well deﬁned due to its rare occurrence. Ap-
proximately 85 cases of SCC of the endometrium have been reported
to date.
In this case study, we report a unique and challenging case that
covers the unusual combination of serous carcinoma of endometrium
with small-cell neuroendocrine. To our knowledge, it represents an
under-reported area of gynecological medicine.itute, 2501N. OrangeAve., Suite
e), sarfraz.ahmad@ﬂhosp.org
. This is an open access article under2. Case presentation
A74-year-old African-American female (BMI 32.9 kg/m2), presented
with intermittent post-menopausal bleeding for more than one month.
She denied any breast, gynecologic and/or colon cancers in her family.
The patient had four spontaneous vaginal deliveries at term.
On transvaginal ultrasound exam, her uterus measured
11 × 6 × 7.1 cm. There were two ﬁbroids noted measuring 3.8 cm and
2.3 cm, along with a 0.8 cm calciﬁcation at the fundus, probably a
small ﬁbroid. Endometrial stripewas 0.3 cm, and the ovaries were unre-
markable. The right ovary measured 1.1 × 0.7 × 1.1 cm, while the left
ovary measured 1.8 × 1.0 × 1.6 cm. The patient's Pap-Smear was nega-
tive. She underwent examination with her gynecologist. For further as-
sessment, endocervical curettage (ECC), endometrial biopsy and
cervical biopsy were obtained that showed a poorly-differentiated car-
cinoma. There was also a polyp from the endocervix which showed
poorly-differentiated carcinoma.
The patient was then seen in consultation with our Gynecologic On-
cology Service. Pathology slides were reviewed at our hospital, which
showed a high-grade poorly differentiated carcinoma with cervical in-
volvement (Figs. 1–3). Pre-operative immunohistochemistry (IHC)
tests showed positivity for keratin, CK7, p63, p16, and focal estrogen re-
ceptor, which raised the possibility of a serous carcinoma. Pathology as-
sessment revealed a malignant neoplasm in all specimens and minute
fragments of high-grade poorly differentiated carcinoma (Figs. 1–3).
A computed tomography (CT) of the chest, abdomen and pelvis was
recommended, given the possibility of a serous carcinoma, and tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Polypoid endometrial small-cell carcinoma (left) and serous intraepithelial carcinoma (H&E, 4×). (B) Serous adenocarcinomawith inﬁltrative glands lined by cells that have a
“hobnail” appearance (H&E, 20×).
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cer which invaded to the level of the uterine serosa, with no evidence of
parametrial invasion ormetastatic disease in the abdomen or pelvis. The
cervix appeared grossly normal and no lymphadenopathy was noted.
On CT of the chest, therewas a 5mmnon-speciﬁc nodule in the anterior
right upper lobe. Recommendationwas for robotic-assisted laparoscop-
ic hysterectomy, bilateral salpingo-oophorectomy, sentinel lymph node
(SLN) mapping, and pelvic-and-aortic lymphadenectomy.
Accordingly, the patient underwent these surgical procedures with-
out issues. At the time of surgery, the patient's uterus was approximate-
ly 8-weeks size. There were some ﬁbroids noted. Tubes and ovaries
appeared normal. The upper abdomen surveyed normal with smooth-
appearing liver surface and diaphragm. The omentum was without ab-
normalities. With SLNmapping, utilizing FireFly technology, there were
green dye positive external iliac lymph nodes bilaterally. These nodes
had no blue dye uptake.
Surgical pathology ﬁndings revealed a stage II, serous endometrial
adenocarcinoma located in the anterior and posterior endometrium,
measuring 9.5 × 7.8 × 2.5 cm with 87% myometrial invasion and
lymphovascular space invasion. Therewas also cervical stromal involve-
ment. Benign nabothian cysts, intramural leiomyomas and a benign
para-tubal cyst on the left fallopian tube were also noted. All 33 lymph
nodes retrieved were negative for malignancy.
Intra-disciplinary tumor board reviewof the post-surgical pathology
showed areas of apparent neuroendocrine differentiation within the
tumor. The IHC showed diffuse immunoreactivity for CD56 within the
tumor,with focal immunoreactivity for synaptophysin. p53was diffuse-
ly immunoreactive, while CD99 was negative (Figs. 1–3). These results
were most consistent with a combined serous adenocarcinoma and
small-cell neuroendocrine carcinomaof the endometrium, each compo-
nent compromising approximately half of the tumor. DNAmismatch re-
pair proteins (MLH1, MSH2, MSH6, and PMS2) were tested by
immunohistochemistry.Fig. 2. (A) Small-cell carcinoma invading the myometrium (H&E, 10×). (BRecommendations from our tumor board was sandwich therapy
consisting of etoposide/cisplatin with whole pelvic radiation. The pa-
tient relocated after surgery closer to her family and was lost to fol-
low-up for 3-months. She was instructed to begin therapy as soon as
possible. Unfortunately, she did not follow through with the treatment
recommendations in a timely manner. She subsequently returned to
our institution with evidence of widespread, progressive disease. Che-
motherapy was initiated. The patient received two-cycles and then re-
fused further treatment. She died of disease (DOD) 2-months thereafter.
3. Comments/discussion
Endometrial cancer is the most common gynecological malignancy
in the United States. Annually, 319,600 women are diagnosed with
this disease worldwide (Torre et al., 2015). Serous carcinoma of the en-
dometrium is a clinically aggressive disease and tends to spread early,
via myometrial invasion, lymphovascular space invasion (LVSI), intra-
abdominal invasion as well as distant spread. Prognosis is generally
poor, with a 50% relapse rate and a 5-year survival rate of 18–27%
(Acharya et al., 2005). The survival rate of womenwith stage I-II disease
is 35–50%, while stage III-IV disease patients show a survival rate of 0–
15% (Acharya et al., 2005).
Small-cell neuroendocrine carcinoma is an extremely rare and ag-
gressive disease of the female genital tract, representing 2% of all gyne-
cological malignancies (Crowder and Tuller, 2007), and 0.8% of all
endometrial carcinomas (Ishida et al., 2014). Proposed diagnostic
criteria by van Hoeven et al. (1995) for small-cell neuroendocrine tu-
mors are as follows: i) uniform, small- to medium-sized tumor cells
form ﬂaky or nested cell mass, which may or may not be associated
with other tumors, such as adenocarcinoma, ii) at least one neuroendo-
crine marker should be positive in IHC examination, and iii) clear evi-
dence of primary SCC of the endometrium must be identiﬁed to
exclude the possibility of invasion or transfer of SCC from other parts) Small-cell carcinoma with perivascular pseudorosettes (H&E, 20×).
Fig. 3. (A) High power image of the tumor demonstrating cells with a high nuclear-cytoplasmic ratio, minimal cytoplasm, nuclear molding, ﬁne chromatin and abnormal mitoses (H&E
40×). (B) The tumor shows diffuse expression of CD56 and was also positive for synaptophysin, keratins and p53 (not shown) (10×).
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consistently positive in cases of small-cell neuroendocrine, include
CD56, chromogranin A, synaptophysin, p53, and p16.
Due to the rarity of this tumor type, there is no standard manage-
ment. Surgery is the mainstay approach, with adjuvant therapy
consisting of chemotherapy and radiotherapy. Because of the histologi-
cal similarities between small-cell neuroendocrine tumor of the endo-
metrium and lung, successful treatment of cases involving the lung
can be extrapolated and applied to cases of the endometrium.
In Eichhorn's review of the literature for caseswith endometrial SCC,
two-thirds of patients with follow-up observation of at least 1-year died
within the year, with recurrences developing in a majority of the re-
maining patients (Eichhorn and Young, 2001). With advanced-stage
disease, and the reported median survival of this pathology is only 5-
months (Matsumoto et al., 2011). In the descriptive review by
Matsumoto et al. (2011) of 53 cases of small-cell disease of the endome-
trium, 20 patients (37.7%)were shown to have long-term (N1 year) sur-
vival, with 17 of those patients (85%) having stage I or II disease while
the three remaining patients (15%) had stage III or IV disease
(Matsumoto et al., 2011). The prognosis of small-cell neuroendocrine
tumors is poor, but early detection along with surgery and adjuvant
therapy may have better patient outcome (Katahira et al., 2004).
Following the publication of Matsumoto et al. (2011), we found
seven new cases of small-cell neuroendocrine carcinoma of the endo-
metrium in peer-reviewed literature, summarised in Table 1. TheTable 1
Review of recent cases of small-cell neuroendocrine carcinoma of the endometrium.
Author
Age
(Year) Stage Associated Neoplasm IHC Markers
Abaid et
al.
(2012)
73 IA Leiomyoma Synaptophysin
Kurtay et
al.
(2012)
67 IB None Synaptophysin
chromogranin
Üreyen et
al.
(2013)
52 IC Polypoid tumor ﬁlling endometrial cavity
that may be uterine sarcoma or a MMMT
NSE, pancytok
weight keratin
35 IIIC Undifferentiated endometrioid carcinoma Unknown
45 IVB Endometrial carcinoma Unknown
Chen et al.
(2014)
50 IB None Synaptophysin
AE1
Ishida et
al.
(2014)
80 IVA Small focus of endometrioid
adenocarcinoma
Synaptophysin
Current
Case,
74 II Serous adenocarcinoma CD56, synapto
CK7, p63, p16,
Abbreviations: IHC= immunohistochemistry, NSE= neuron-speciﬁc enolase, Chemo= chem
Mullerian tumor.mean age at time of consultation was 57.4 years, which correlates
with Matsumoto's ﬁndings of mean age of 60 years (Matsumoto et al.,
2011). Four patients (57.1%) had stage I disease, one patient (14.3%)
had stage III disease, while the remaining two (28.6%) had stage IV dis-
ease (Table 1). Associated neoplasms were present in ﬁve patients
(71.4%), while the remaining two (28.6%) presented small-cell neuro-
endocrine tumor exclusively. The IHCmarkers were notedwith ﬁve pa-
tients, in which they all tested positive for synaptophysin and CD56,
among other markers (Table 1). All patients underwent surgery and
chemotherapy, with four patients (57.1%) having etoposide/cisplastin
included in their regimen. Furthermore, three patients (42.9%)
underwent radiotherapy, in addition to surgery and chemotherapy
(Table 1). Patient outcomewas reported in ﬁve cases, with four patients
(80%) alive at the time of publication, while one patient (20%) died of
the disease 7-months post-diagnosis (Table 1). The deceased patient
had stage IV disease, and followed the pattern of early deathwith an ad-
vanced-stage tumor of this type, emphasizing the signiﬁcance of early
detection. Our patient did not seek care for adjuvant therapy after
relocating and DOD at 6-months post-operatively.
This extremely rare combination of tumors presents a challenge for
treatment. The mainstay of treatment seems to be surgery followed by
chemotherapy ± radiation therapy. Although small-cell neuroendo-
crine tumors are rarely seen in the endometrium, its prevalence in
other sites such as the lung has allowed for extrapolation of adjuvant
chemotherapy regimens that may be successful. Early detectionTreatments Outcomes
, pancytokeratin, CD56 Surgery, Chemo (etoposide/cisplastin) Unknown
, NSE, CD56,
A
Surgery, Chemo (etoposide/cisplastin) and
radiotherapy
NED at
6-months
eratin, low-molecular Surgery, Chemo (etoposide/cisplastin) and
radiotherapy
NED at
58-months
Surgery, Chemo (cisplastin/adriamycin) and
radiotherapy
NED at
13-years
Surgery, Chemo
(endoxan/doxorubicin/vincristine followed
by etoposide/cisplastin)
DOD after
7-months
, CD56, Ki67, antikeratin Surgery, Chemo (paclitaxel/carboplatin) NED at
2-years
, CD56, chromogranin A Surgery, Chemo (paclitaxel/carboplatin) Unknown
physin, p53, keratin,
focal estrogen receptor
Surgery, Chemo (etoposide/cisplatin) and
radiotherapy
Died at
6-months
otherapy, DOD=died of disease, NED=no evidence of disease, MMMT=malignantmix
82 L.A. Brudie et al. / Gynecologic Oncology Reports 17 (2016) 79–82remains a major prognostic factor in small-cell neuroendocrine tumors,
along with prompt surgical and adjuvant therapy.
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